BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

B1233	**UROGENITAL MYCOPLASMA BROTH BASE (MYCOPLASMA UROGENITAL BROTH BASE)**

Formula

Ingredients:gms/lit.

Heart infusion powder	8.00
Casein enzymichydrolysate	8.00
Yeast extract	4.00
Sodium chloride	3.50
Arginine hydrochloride	5.00
Cysteine hydrochloride	0.10
Phenol red	0.05

Final pH (at 25°C) : 6.3± 0.2

Directions :

Suspend 14.33 grams in 425 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool the medium and aseptically add rehydrated contents of 1 vial of Vitamino Growth Supplement (BF037), 1 vial of Urea Solution (BF124), 50 ml Horse serum (BF021) and 1 vial of Mycoplasma Urogenital Selective Supplement (BF123). Mix well and dispense as desired.

Principle :

The medium contains casein enzymichydrolysate and heart infusion powder, which provide necessary nutrients for the growth of Mycoplasma and Ureaplasma. Yeast extract provides preformed nucleic acid precursors, necessary for the growth of fastidious Mycoplasma. Many Mycoplasmas require serum for their good growth and also presence of antibiotics (present in Mycoplasma Urogenital Selective Supplement, BF123) is necessary to prevent the growth of accompanying microbial flora. Sodium chloride maintains the osmotic balance. Phenol red acts as a pH indicator. M. hominis metabolizes arginine to ammonia via ornithine by a three-enzyme system, resulting in increase in the pH of the medium which is indicated by a colour change to red. Ureaplasma possess the enzyme urease and breakdown urea to ammonia indicated by a colour change to red-orange. Additional tests are required for the differentiation between M. hominis and U. urealyticum.A negative broth should remain clear or may show a faint haze.

QC Tests – (I)Dehydrated Medium		
	Colour :	Light yellow to pink
	Appearance :	Homogeneous Free Flowing powder
(II)Rehydrated medium		
	pH (post autoclaving/heating) :	6.3 ± 0.2
	Colour (post autoclaving/heating) :	Reddish pink
	Clarity (post autoclaving/heating) :	Clear solution in tubes
(III)Q.C. Test Microbiological		
	Cultural characteristics observed after an incubation at 35-37°C for 48 hours to one week.with added Vitamino Growth Supplement (BF037), Urea Solution (BF124), Horse Serum (BF021) and Mycolasma Urogenital Selective Supplement (BF123).	

	MICROORGANISM (ATCC)	GROWTH	Arginine	Urea
	Mycoplasma hominis(14027)	Good -luxuriant	positive reaction, red colour	Negative reaction,no colour change
	Ureaplasmaurealyticum (27618()	Good -luxuriant	negative reaction, no red colour	positive reaction, redorange colour

Precautions :	1. For Laboratory Use.
	2. Follow proper, established laboratory procedures in handling and disposing of infectious materials.
Limitations :	1. Since the nutritional requirements of organisms vary, some strains may be encountered that fail to grow or grow poorly on this medium.

BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

Use :	It is recommended for selective cultivation of Mycoplasma hominis and Ureaplasma urealyticum .				
Storage :	Dehydrated medium- below 30°C Prepared medium– Between 2 to 8°C.				
Packing :	500 gm. bottle				
Product profile:	Reconstitution	Quantity on Preparation (500g)	pH (25°C)	Supplement	Sterilization
B1233	28.65g/l	17.45L	6.3 ± 0.2	Vitamino Growth Supplement (BF037), Urea Solution (BF124), Horse Serum (BF021) and Mycolasma Urogenital Selective Supplement (BF123)	121^0C / 15 minutes

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.
The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

Rev: December 2020